2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Sunday, October 21, 2018

9:00AM-11:00AM: Abstract Number: 547

Corticosteroid Bridging Strategies with Methotrexate Monotherapy in Early Rheumatoid and Undifferentiated Arthritis; A Comparison of Efficacy and Toxicity in 2 Clinical Trials

Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

9:00AM-11:00AM: Abstract Number: 627

Corticosteroid Utilization before and after Initiation of Biologic Dmards between Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

9:00AM-11:00AM: Abstract Number: 642

Cost of Illness Analysis before and after Initiation of Tumour Necrosis Factor α Inhibitors in Patients with Axial Spondyloarthritis

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment

9:00AM-11:00AM: Abstract Number: 191

Creation of an Immunology Series Video Library in Facilitating Basic Immunology Knowledge Acquisition and Retention Amongst Adult Rheumatology Trainees

Education Poster

9:00AM-11:00AM: Abstract Number: 335

Cross-Cultural Validity of Functional Status Assessment Measures for Rheumatoid Arthritis

Measures and Measurement of Healthcare Quality Poster I

9:00AM-11:00AM: Abstract Number: 115

CTLA4-Ig/CD86 Interaction on Cultered Human Fibrocytes and Fibroblasts from Systemic Sclerosis Patients

Systemic Sclerosis and Related Disorders – Basic Science Poster I

9:00AM-11:00AM: Abstract Number: 817

Current Diagnostic Delays in Vasculitis and Factors Associated with Time to Diagnosis

Vasculitis Poster I: Non-ANCA-Associated and Related Disorders

9:00AM-11:00AM: Abstract Number: 758

Cutaneous Lupus Erythematosus Patients with a Negative ANA Meeting Acr and/or SLICC Criteria for Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

9:00AM-11:00AM: Abstract Number: 53

Cyclin-Dependent Kinase 4/6 Inhibitor: A Promising Development Candidate Targeting Synovial Hypertrophy for Rheumatoid Arthritis Treatment

Rheumatoid Arthritis – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 772

Cytomegaloviral or Pneumocystis Jiroveci Pneumonia Increases Mortality Rate in Systemic Lupus Erythematosus Patients with Pulmonary Hemorrhage: Evidence from Bronchoalveolar Lavage Fluid Analysis

Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

9:00AM-11:00AM: Abstract Number: 18

Cytoplasmic FOXO1 Identifies Novel Disease-Activity Associated B Cell Subsets in SLE

B Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 589

DAS28-CRP Versus DAS28-ESR and Thresholds for Disease Activity Category: Blinded Data from the Ongoing Phase IIb Trial with the EP4 Receptor Antagonist CR6086 in DMARD-Naïve Patients with Early Rheumatoid Arthritis

Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

9:00AM-11:00AM: Abstract Number: 99

DC-Hil+ Myeloid-Derived Suppressor Cells Are Elevated in the Peripheral Blood and Lesional Skin of Cutaneous Lupus Patients

Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 78

Decreased B Cell Ataxia-Telangiectasia Mutated Expression and Receptor Diversity Identify a Subset of Rheumatoid Arthritis Patients with Increased Joint Erosion Prevalence

Rheumatoid Arthritis – Etiology and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 176

Deductive Anatomy By Self-Examination. a Novel Method to Reinforce Traditional Teaching of Musculoskeletal Anatomy

Education Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].